Core Viewpoint - Baosai Tu-B (02315) has seen a significant stock price increase of over 5%, currently trading at HKD 47.96, with a transaction volume of HKD 69.87 million. The company has released its revenue forecast for the fiscal year 2025, indicating substantial growth in both revenue and net profit compared to the previous year [1]. Financial Performance - The company expects to achieve revenue between RMB 1.369 billion and RMB 1.389 billion for the fiscal year 2025, representing an increase of RMB 389 million to RMB 408 million year-on-year, with a growth rate of 39.61% to 41.65% [1]. - The projected net profit attributable to shareholders is expected to be between RMB 162 million and RMB 182 million, reflecting an increase of RMB 129 million to RMB 149 million year-on-year, with a significant growth rate of 384.26% to 443.88% [1]. Business Development - Guolian Minsheng Securities (601456) highlights that the high demand for innovative animal models and preclinical CRO services is driving substantial revenue growth for the company. The firm notes that since 2025, the company has established external licensing agreements with several leading domestic and international pharmaceutical companies [1]. - The approval of multiple pipelines for IND (Investigational New Drug) is expected to further enhance the company's revenue potential through milestone payments as these licensed pipelines progress, thereby opening up additional growth opportunities [1].
百奥赛图-B再涨超5% 主业景气带动收入高增 机构看好公司长期增长潜力